Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F. Swinnen SG, et al. Among authors: aronson r. Diabetes Care. 2010 Jun;33(6):1176-8. doi: 10.2337/dc09-2294. Epub 2010 Mar 3. Diabetes Care. 2010. PMID: 20200301 Free PMC article. Clinical Trial.
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. Riddle MC, et al. Among authors: aronson r. Diabetes Care. 2013 Sep;36(9):2497-503. doi: 10.2337/dc12-2462. Epub 2013 Apr 5. Diabetes Care. 2013. PMID: 23564915 Free PMC article. Clinical Trial.
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.
Conget I, Castaneda J, Petrovski G, Guerci B, Racault AS, Reznik Y, Cohen O, Runzis S, de Portu S, Aronson R; OpT2mise Study Group. Conget I, et al. Among authors: aronson r. Diabetes Technol Ther. 2016 Jan;18(1):22-8. doi: 10.1089/dia.2015.0159. Epub 2015 Aug 4. Diabetes Technol Ther. 2016. PMID: 26241790 Free PMC article. Clinical Trial.
Response to Letter to the Editor Regarding OpT2mise Study.
Conget I, Aronson R, Cohen O, Reznik Y. Conget I, et al. Among authors: aronson r. Diabetes Technol Ther. 2016 Jul;18(7):448. doi: 10.1089/dia.2016.0081. Epub 2016 Apr 4. Diabetes Technol Ther. 2016. PMID: 27043892 No abstract available.
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Rosenstock J, et al. Among authors: aronson r. Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23. Diabetes Care. 2016. PMID: 27222510 Free article. Clinical Trial.
307 results